MX2021003478A - Compuestos utiles como inhibidores de cinasa. - Google Patents

Compuestos utiles como inhibidores de cinasa.

Info

Publication number
MX2021003478A
MX2021003478A MX2021003478A MX2021003478A MX2021003478A MX 2021003478 A MX2021003478 A MX 2021003478A MX 2021003478 A MX2021003478 A MX 2021003478A MX 2021003478 A MX2021003478 A MX 2021003478A MX 2021003478 A MX2021003478 A MX 2021003478A
Authority
MX
Mexico
Prior art keywords
compounds
kinase inhibitors
compounds useful
tyrosine kinase
inhibitors
Prior art date
Application number
MX2021003478A
Other languages
English (en)
Inventor
Nicolas Guisot
Original Assignee
Loxo Oncology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1522245.8A external-priority patent/GB201522245D0/en
Priority claimed from GBGB1613945.3A external-priority patent/GB201613945D0/en
Application filed by Loxo Oncology Inc filed Critical Loxo Oncology Inc
Publication of MX2021003478A publication Critical patent/MX2021003478A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/08—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Abstract

La presente invención se refiere a compuestos novedosos. Los compuestos de la invención son inhibidores de tirosina cinasa. Específicamente, los compuestos de la invención son útiles como inhibidores de la tirosina cinasa de Bruton (BTK). La invención también contempla el uso de los compuestos para tratar condiciones tratables por la inhibición de la tirosina cinasa de Bruton, por ejemplo cáncer, linfoma, leucemia y enfermedades inmunológicas.
MX2021003478A 2015-12-16 2016-12-16 Compuestos utiles como inhibidores de cinasa. MX2021003478A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1522245.8A GB201522245D0 (en) 2015-12-16 2015-12-16 Compounds useful as kinase inhibitors
GBGB1613945.3A GB201613945D0 (en) 2016-08-15 2016-08-15 Compounds useful as kinase inhibitors
PCT/GB2016/053968 WO2017103611A1 (en) 2015-12-16 2016-12-16 Compounds useful as kinase inhibitors

Publications (1)

Publication Number Publication Date
MX2021003478A true MX2021003478A (es) 2022-07-25

Family

ID=57590725

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2021003478A MX2021003478A (es) 2015-12-16 2016-12-16 Compuestos utiles como inhibidores de cinasa.
MX2018007267A MX2018007267A (es) 2015-12-16 2016-12-16 Compuestos utiles como inhibidores de cinasa.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2018007267A MX2018007267A (es) 2015-12-16 2016-12-16 Compuestos utiles como inhibidores de cinasa.

Country Status (34)

Country Link
US (7) US10695323B2 (es)
EP (2) EP3390395B1 (es)
JP (3) JP6731483B2 (es)
KR (2) KR102215792B1 (es)
CN (9) CN113603645A (es)
AU (4) AU2016373530B2 (es)
CA (1) CA3008488C (es)
CL (1) CL2018001591A1 (es)
CO (1) CO2018006164A2 (es)
CR (1) CR20180367A (es)
CY (1) CY1123561T1 (es)
DK (1) DK3390395T3 (es)
EA (1) EA035132B1 (es)
ES (1) ES2828431T3 (es)
FI (1) FIC20240004I1 (es)
HK (1) HK1263254A1 (es)
HR (1) HRP20201835T1 (es)
HU (2) HUE051921T2 (es)
IL (4) IL285976B2 (es)
LT (1) LT3390395T (es)
MA (2) MA55064A (es)
MD (1) MD3390395T2 (es)
MX (2) MX2021003478A (es)
NZ (1) NZ743553A (es)
PE (3) PE20181449A1 (es)
PH (1) PH12018501268A1 (es)
PT (1) PT3390395T (es)
RS (1) RS60982B1 (es)
SG (2) SG10202012498TA (es)
SI (1) SI3390395T1 (es)
TN (1) TN2018000213A1 (es)
UA (2) UA122258C2 (es)
WO (1) WO2017103611A1 (es)
ZA (4) ZA201804137B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201410430D0 (en) 2014-06-11 2014-07-23 Redx Pharma Ltd Compounds
EA201890730A1 (ru) 2015-09-16 2018-10-31 Локсо Онколоджи, Инк. Производные пиразолопиримидина в качестве ингибиторов btk для лечения злокачественного новообразования
WO2017103611A1 (en) 2015-12-16 2017-06-22 Redx Pharma Plc Compounds useful as kinase inhibitors
GB201801226D0 (en) 2018-01-25 2018-03-14 Redx Pharma Plc Modulators of Rho-associated protein kinase
KR20210028144A (ko) * 2018-04-06 2021-03-11 블랙 벨트 티엑스 리미티드 Atf6 저해제 및 그의 용도
CN112119063B (zh) * 2018-05-18 2023-10-17 富士胶片株式会社 3-二氟甲基吡唑化合物的制造方法及3-二氟甲基吡唑-4-羧酸化合物的制造方法以及吡唑烷化合物
JP7286755B2 (ja) 2018-07-31 2023-06-05 ロクソ オンコロジー， インコーポレイテッド （ｓ）－５－アミノ－３－（４－（（５－フルオロ－２－メトキシベンズアミド）メチル）フェニル）－１－（１，１，１－トリフルオロプロパン－２－イル）－１ｈ－ピラゾール－４－カルボキサミドの噴霧乾燥分散体および製剤
WO2021028645A1 (en) 2019-08-09 2021-02-18 Kalvista Pharmaceuticals Limited Plasma kallikrein inhibitors
US20220273593A1 (en) * 2019-09-19 2022-09-01 Johann Wolfgang Goethe-Universität Frankfurt am Main Compounds and compositions for treating kidney disease
CN110724135B (zh) * 2019-11-18 2023-04-28 上海医药工业研究院有限公司 一种艾拉普林中间体及其制备方法
JP7142173B2 (ja) 2019-12-06 2022-09-26 ロクソ オンコロジー， インコーポレイテッド ブルトン型チロシンキナーゼ阻害剤の投薬
US20230145305A1 (en) * 2020-03-12 2023-05-11 Fochon Biosciences, Ltd. Compounds useful as kinase inhibitors
TWI809489B (zh) * 2020-09-10 2023-07-21 美商絡速藥業公司 用於製備(s)-5-胺基-3-(4-((5-氟-2-甲氧基苯甲醯胺基)甲基)苯基)-1-(1,1,1-三氟丙烷-2-基)-1h-吡唑-4-甲醯胺之方法及中間體
CN112386597B (zh) * 2020-10-15 2022-03-15 天津济坤医药科技有限公司 泽布替尼在制备治疗肺纤维化疾病药物中的应用
US20240100172A1 (en) 2020-12-21 2024-03-28 Hangzhou Jijing Pharmaceutical Technology Limited Methods and compounds for targeted autophagy
WO2022228302A1 (en) * 2021-04-25 2022-11-03 Bionova Pharmaceuticals (Shanghai) Limited Heteroaromatic carboxamide compounds and its use
KR20230171449A (ko) 2021-05-14 2023-12-20 록쏘 온콜로지, 인코포레이티드 브루톤 티로신 키나제 억제제의 공결정질 형태
CA3223769A1 (en) * 2021-07-01 2023-01-05 Xinglu ZHOU Bruton's tyrosine kinase and mutant degrader, composition and application thereof
CN115611810A (zh) * 2021-07-16 2023-01-17 深圳市塔吉瑞生物医药有限公司 取代的吡唑类化合物及包含该化合物的组合物及其用途
WO2023110970A1 (en) 2021-12-14 2023-06-22 Netherlands Translational Research Center Holding B.V Macrocyclic btk inhibitors
WO2023143355A1 (en) * 2022-01-28 2023-08-03 Hansoh Bio Llc Azacycle amide derivative, preparation methods and medicinal uses thereof
WO2023174397A1 (en) * 2022-03-18 2023-09-21 Insilico Medicine Ip Limited Pyrazole membrane-associated tyrosine-and threonine-specific cdc2-inhibitory kinase (pkmyt1) inhibitors and uses thereof
CN115894376A (zh) * 2022-12-15 2023-04-04 南京雷正医药科技有限公司 一种芳香族酰胺类化合物、药物组合物及其用途

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6921763B2 (en) 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
SK3812002A3 (en) 1999-09-17 2003-09-11 Abbott Gmbh & Co Kg Pyrazolopyrimidines as therapeutic agents
US6291504B1 (en) * 1999-10-20 2001-09-18 Dupont Pharmaceuticals Company Acylsemicarbazides and their uses
US20030225098A1 (en) 2002-03-21 2003-12-04 Hirst Gavin C. Kinase inhibitors
DK2526933T3 (en) 2006-09-22 2015-05-18 Pharmacyclics Inc Inhibitors of Bruton's tyrosine kinase
WO2008063287A2 (en) * 2006-10-06 2008-05-29 Abbott Laboratories Novel imidazothiazoles and imidazoxazoles
CA2668286C (en) 2006-11-03 2014-09-16 Pharmacyclics, Inc. Bruton's tyrosine kinase activity probe and method of using
CN101674834B (zh) 2007-03-28 2013-06-12 环状药物公司 布鲁顿氏酪氨酸激酶(Bruton's tyrosine kinase)抑制剂
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
CA2986640C (en) 2008-06-27 2019-03-26 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
US20110224235A1 (en) 2008-07-16 2011-09-15 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors
BRPI0916356B1 (pt) * 2008-07-24 2022-08-23 Nerviano Medical Sciences S.R.L 3,4-diaril pirazois como inibidores da proteína quinase
US8426428B2 (en) 2008-12-05 2013-04-23 Principia Biopharma, Inc. EGFR kinase knockdown via electrophilically enhanced inhibitors
US7718662B1 (en) * 2009-10-12 2010-05-18 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase
NZ772688A (en) 2010-06-03 2022-09-30 Pharmacyclics Llc The use of inhibitors of bruton’s tyrosine kinase (btk)
CA2803292C (en) 2010-06-30 2016-06-14 Ironwood Pharmaceuticals, Inc. Sgc stimulators
KR102052670B1 (ko) 2011-05-17 2019-12-06 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 키나아제 저해제
MX347040B (es) 2011-05-17 2017-04-10 Principia Biopharma Inc Inhibidores de tirosina-cinasas.
AU2012283775A1 (en) 2011-07-13 2014-01-23 Pharmacyclics Llc Inhibitors of Bruton's tyrosine kinase
EP2548877A1 (en) 2011-07-19 2013-01-23 MSD Oss B.V. 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
CA2874461C (en) 2012-06-18 2021-10-12 Principia Biopharma Inc. Formulations containing reversible covalent compounds
US9572811B2 (en) 2012-08-03 2017-02-21 Principia Biopharma Inc. Treatment of dry eye
KR20150040292A (ko) * 2012-08-10 2015-04-14 베링거 인겔하임 인터내셔날 게엠베하 브루톤 티로신 키나제 (ｂｔｋ) 억제제로서의 헤테로방향족 화합물
GB201214750D0 (en) * 2012-08-17 2012-10-03 Respivert Ltd Compounds
MD20150035A2 (ro) * 2012-11-02 2015-10-31 Pfizer Inc. Inhibitori de tirozinkinaza Bruton
CN103848810A (zh) 2012-11-30 2014-06-11 北京赛林泰医药技术有限公司 鲁顿酪氨酸激酶抑制剂
US8957080B2 (en) 2013-04-09 2015-02-17 Principia Biopharma Inc. Tyrosine kinase inhibitors
GB201309085D0 (en) 2013-05-20 2013-07-03 Redx Pharma Ltd Compounds
EP3052476B1 (en) * 2013-09-30 2020-07-15 Guangzhou InnoCare Pharma Tech Co., Ltd. Substituted nicotinimide inhibitors of btk and their preparation and use in the treatment of cancer, inflammation and autoimmune disease
WO2015075051A1 (en) * 2013-11-19 2015-05-28 Universitaet Des Saarlandes Allosteric inhibitors of atypical protein kinases c
EP3082809B1 (en) 2013-12-20 2021-01-20 Merck Sharp & Dohme Corp. Btk inhibitors
KR20160117614A (ko) 2014-02-21 2016-10-10 프린시피아 바이오파마, 인코퍼레이티드 Btk 억제제의 염 및 고체 형태
GB201404987D0 (en) 2014-03-20 2014-05-07 Redx Pharma Ltd Compounds
CN105085474B (zh) * 2014-05-07 2018-05-18 北京赛林泰医药技术有限公司 鲁顿酪氨酸激酶抑制剂
GB201410430D0 (en) 2014-06-11 2014-07-23 Redx Pharma Ltd Compounds
EA032530B1 (ru) 2015-01-28 2019-06-28 Байер Фарма Акциенгезельшафт 4h-пирроло[3,2-c]пиридин-4-оновые производные
GB2548542A (en) * 2015-06-16 2017-09-27 Redx Pharma Plc Compounds
EA201890730A1 (ru) 2015-09-16 2018-10-31 Локсо Онколоджи, Инк. Производные пиразолопиримидина в качестве ингибиторов btk для лечения злокачественного новообразования
JOP20160198B1 (ar) 2015-09-16 2022-03-14 Janssen Pharmaceuticals Inc مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JO3633B1 (ar) 2015-09-16 2020-08-27 Katholieke Univ Leuven Ku Leuven Research & Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
WO2017103611A1 (en) 2015-12-16 2017-06-22 Redx Pharma Plc Compounds useful as kinase inhibitors
TWI726017B (zh) 2015-12-16 2021-05-01 德商百靈佳殷格翰國際股份有限公司 做為布魯頓式酪胺酸激酶（ｂｔｋ）抑制劑之雜芳族化合物
CN108602813B (zh) 2015-12-16 2021-10-29 百时美施贵宝公司 作为apj受体激动剂的杂芳基羟基嘧啶酮
CA3008648C (en) 2015-12-16 2023-01-10 Priostar Pty Ltd Dendrimer and formulations thereof
WO2017106623A1 (en) 2015-12-16 2017-06-22 Ecolab Usa Inc. Peroxyformic acid compositions for membrane filtration cleaning

Also Published As

Publication number Publication date
JP6731483B2 (ja) 2020-07-29
KR20210018530A (ko) 2021-02-17
ZA202107472B (en) 2023-03-29
CN114591242A (zh) 2022-06-07
NZ743553A (en) 2022-08-26
HK1263254A1 (zh) 2020-02-21
US20220062239A1 (en) 2022-03-03
US10918622B2 (en) 2021-02-16
CN108473481A (zh) 2018-08-31
AU2021201811B2 (en) 2022-01-27
LT3390395T (lt) 2020-11-25
CY1123561T1 (el) 2022-03-24
JP7419437B2 (ja) 2024-01-22
IL281067A (en) 2021-04-29
US20200276162A1 (en) 2020-09-03
EP3782994A1 (en) 2021-02-24
JP2020172535A (ja) 2020-10-22
US11471441B2 (en) 2022-10-18
AU2016373530B2 (en) 2021-01-21
IL276283A (en) 2020-09-30
HUE051921T2 (hu) 2021-03-29
CN113636978A (zh) 2021-11-12
SI3390395T1 (sl) 2020-11-30
CN114573510A (zh) 2022-06-03
KR102215792B1 (ko) 2021-02-16
AU2021225161A1 (en) 2021-09-30
ZA202100544B (en) 2023-06-28
BR112018012341A2 (pt) 2018-12-04
PT3390395T (pt) 2020-11-03
US10695323B2 (en) 2020-06-30
JP2018538307A (ja) 2018-12-27
IL259923B (en) 2020-08-31
US10464905B2 (en) 2019-11-05
EP3390395B1 (en) 2020-09-09
US20190000806A1 (en) 2019-01-03
IL285976A (en) 2021-10-31
SG11201805044WA (en) 2018-07-30
FIC20240004I1 (fi) 2024-03-01
ES2828431T3 (es) 2021-05-26
CO2018006164A2 (es) 2018-09-20
JP2022120013A (ja) 2022-08-17
CL2018001591A1 (es) 2018-09-28
CN114634447A (zh) 2022-06-17
HRP20201835T1 (hr) 2021-01-08
MD3390395T2 (ro) 2021-02-28
DK3390395T3 (da) 2020-09-28
IL281067B (en) 2022-04-01
MA55064A (fr) 2021-09-29
AU2021201811A1 (en) 2021-04-22
CR20180367A (es) 2018-11-12
UA127863C2 (uk) 2024-01-31
AU2021225162A1 (en) 2021-09-30
US20210093611A1 (en) 2021-04-01
IL285976B2 (en) 2023-10-01
EA035132B1 (ru) 2020-04-30
CA3008488C (en) 2023-10-10
UA122258C2 (uk) 2020-10-12
IL276283B (en) 2021-03-25
US11826351B2 (en) 2023-11-28
JP7086140B2 (ja) 2022-06-17
PH12018501268A1 (en) 2019-02-18
MX2018007267A (es) 2018-11-09
PE20181449A1 (es) 2018-09-12
ZA201804137B (en) 2022-08-31
EP3390395A1 (en) 2018-10-24
IL259923A (en) 2018-07-31
CA3008488A1 (en) 2017-06-22
CN114605327A (zh) 2022-06-10
IL285976B1 (en) 2023-06-01
MA49809A1 (fr) 2021-08-31
PE20220507A1 (es) 2022-04-07
AU2016373530A1 (en) 2018-07-05
CN108473481B (zh) 2022-04-19
ZA202107471B (en) 2023-03-29
CN114716381A (zh) 2022-07-08
KR20180115261A (ko) 2018-10-22
RS60982B1 (sr) 2020-11-30
PE20220502A1 (es) 2022-04-07
CN113603645A (zh) 2021-11-05
US10342780B2 (en) 2019-07-09
SG10202012498TA (en) 2021-01-28
CN114621146A (zh) 2022-06-14
US20190135762A1 (en) 2019-05-09
TN2018000213A1 (en) 2019-10-04
US20180362512A1 (en) 2018-12-20
AU2021225161B2 (en) 2023-08-03
AU2021225162B2 (en) 2023-08-03
US20230372298A1 (en) 2023-11-23
EA201891268A1 (ru) 2018-11-30
HUS2400003I1 (hu) 2024-03-28
WO2017103611A1 (en) 2017-06-22

Similar Documents

Publication Publication Date Title
PH12018501268A1 (en) Compounds useful as kinase inhibitors
PH12018500587A1 (en) Pyrazolopyrimidine derivatives as btk inhibitors for the treatment of cancer
PH12017502203A1 (en) Tyrosine kinase inhibitors
PH12018502102A1 (en) Pyrrolotriazine compounds as tam inhibitors
EA201990187A1 (ru) Антипролиферационные средства на основе пиримидина
PH12015502028A1 (en) Ido inhibitors
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
MX366875B (es) Inhibidores de indoleamina 2,3-dioxigenasa (ido).
PH12018502497A1 (en) Adenosine derivatives for use in the treatment of cancer
WO2019035863A8 (en) PYRUVATE KINASE ACTIVATORS FOR USE IN THE TREATMENT OF HEMATOLOGICAL DISORDERS
PH12019502363A1 (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
MX2020006365A (es) Quinazolinonas como inhibidores de poli(adenosin difosfato-ribosa)polimerasa 14 (parp14).
PH12019500196A1 (en) Compounds and compositions and uses thereof
PH12018502314A1 (en) Enhancer of zeste homolog 2 inhibitors
MX2015010983A (es) Inhibidores de tirosina-cinasa de bruton.
MX2020012281A (es) Composiciones que comprenden compuestos de bisfluoroalquil-1,4-ben zodiacepinona y metodos de uso de las mismas.
PH12019500198A1 (en) Compounds and compositions and uses thereof
WO2019036417A3 (en) Inhibition of ngly1 for the treatment of cancer
MX2019000542A (es) Derivados de pirazolilaminobenzimidazol como inhibidores de jak.
MX2015010820A (es) Inhibidores de tirosina cinasa de bruton.
PH12017501063A1 (en) Compounds for the treatment of cancer